Fellowship

Hiatt Vascular Medicine Fellowship

Train the next generation of vascular medicine specialists

Activities

  • Work with project teams on all aspects of clinical trial design, conduct and data interpretation
  • In-depth experience in a specific clinical trial
  • Opportunities and mentorship to become academically productive with emphasis on abstract presentations, manuscript publication

Acquire proficiency in:

  • interpretation of vascular diagnostic studies (physiologic, duplex, angiographic)
  • evaluation and management of atherosclerotic disease (diagnosis, prevention, treatment)
  • diagnosis and management of rare arterial diseases (fibromuscular dysplasia, segmental arterial mediolysis, genetic arteriopathies)
  • assessment of digital ischemia
  • evaluation of venous disorders (thrombosis, reflux, May-Thurner’s)

Duration

Year 1, 60% clinical, 40% research
Optional Year 2, 100% research

Candidates

Completing medical residency or cardiology fellowship

Contact

Email expression of interest and CV to:

Kevin Rogers, MD
Associate Professor of Medicine
Director, Vascular Medicine Fellowship, University of Colorado

Marc Bonaca, MD, MPH
Professor of Medicine, University of Colorado
Executive Director, CPC Clinical Research

Click here to learn more about the University of Colorado Vascular Medicine Fellowship

Our Current Fellows

Interviews with our current fellows, Mario Canonico, MD and Robert Wilson King, MD, and Mark Nehler, MD, Professor of Surgery.

Mario Enrico Canonico, MD

Click above to watch interview

Robert Wilson King, MD

Click above to watch interview

Current Fellow Publications

Mario Enrico Canonico

Canonico ME, Hsia J, Guthrie N L …Bonaca M P (2022). Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial. Clinical Cardiology, 10.1002/clc.23853

Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) are underutilized in 2021 in patients with heart failure with or without diabetes (abstr). Diabetes 1 June 2022; 71 (Supplement_1): 868–P

Canonico ME, Hsia J Hess CN, Bonaca MP. Guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease (PAD)(abstr). Vasc Med, in press

Canonico ME, Capell W, Anand SS…Bonaca MP. Causes of Death in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD (abstr). Circulation, in press

Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) are underutilized in 2021-22 in patients with heart failure without diabetes (abstr). Circulation, in press

Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) for heart failure are underutilized in 2021-2 in patients with chronic kidney disease (abstr), J Am Soc Nephrol, in press

Robert Wilson King

Hogan SE, Nehler MR, Anand S….King RW…Bonaca MP. (2022). Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med, 1358863X221085606

King RW, Bonaca MP. (2021). Acute aortic syndromes: a review of what we know and future considerations. Eur Heart J. Acute CV Care 10(10),1197–1203 https://doi.org/10.1093/ehjacc/zuab106

King RW, Nehler M. R., Patel MR…Bonaca MP. (2022) Risk Stratification for Amputation in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD (abstr). Circulation, in press

Past Fellow Publications

Cullen Buchanan: Current position cardiology fellow

Hogan SE …Buchanan, C… Bonaca MP. (2022). Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med, 1358863X221085606

Hess CN, Nehler MR, Morrison JT, Buchanan C… Bonaca M.P. Pragmatic Implementation Science in Peripheral Artery Disease: Design and Conduct of OPTIMIZE PAD-1 (abstr), Vasc Med, in press

Buchanan C, Hogan SE..Hsia J. Exercise therapy for symptomatic peripheral artery disease following surgical and endovascular peripheral revascularization: could we do better? (abstr) Vasc Med, in press

Buchanan CE, Szarek M, Debus ES… Bonaca MP. Lower May Not Be Better: Systolic Blood Pressure and Risk of Major Adverse Limb Events in Patients with Symptomatic Peripheral Artery Disease after Revascularization: Insights from VOYAGER PAD (abstr). Circulation, in press

Nick Govsyeyev: Current position resident in surgery - vascular

Debus, ES, Nehler MR, Govsyeyev N…Bonaca, M. P. (2021). Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation 144(14),1104–1116

Govsyeyev N, Malgor RD, Hoffman C et al. (2021). A systematic review and meta-analysis of outcomes after acute limb ischemia in patients with cancer. J Vasc Surg 74(3), 1033–1040.e1

Govsyeyev N, Nehler MR, Hiatt WR, Bonaca MP. (2020). Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Current Cardiol Rep 22(3), 13

Govsyeyev N, Nehler MR, Low Wang CC… Bonaca MP. (2022). Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. J Vasc Surg 75(2), 660–670.e3